Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 52
Filter
1.
Eur J Endocrinol ; 173(1): 9-17, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25850829

ABSTRACT

OBJECTIVE: Primary hyperparathyroidism (PHPT) has been associated with low-grade inflammation and increased risk of cardiovascular disease (CVD). The aim of the study was to investigate systemic levels of pro-inflammatory proteins that previously have not been examined in patients with PHPT. The selection of the pro-inflammatory biomarkers included in this study, MMP9, S100A4, S100A8/A9 and the receptors sCD14 and RAGE, was based on a previous microarray screen of mRNAs in adipose tissue from PHPT patients. DESIGN: A prospective study was conducted on a total of 57 patients with PHPT and a control group of 20 healthy blood donors. METHODS: PHPT patients with normalisation of serum calcium levels after parathyroidectomy were followed for 6 months. Forty-two patients participated in the longitudinal study, in which blood samples were taken at inclusion, and 1, 3 and 6 months after surgery. RESULTS: We observed increased serum levels of MMP9 (P=0.029), S100A4 (P<0.001) and sCD14 (P=0.002) in the 57 patients with PHPT compared to the control-group. During 6 months of follow up, S100A4 (P=0.022) and sCD14 (0.002) decreased significantly, while serum levels of MMP9 increased (P=0.025). CONCLUSIONS: The results demonstrate an increased inflammatory response in PHPT patients shown by elevated MMP9, S100A4 and sCD14 at inclusion. During the 6 months of follow-up, MMP9 increased further, possibly due to the tissue repair process after parathyroidectomy. S100A4 and sCD14 decreased after surgery demonstrating a partial reversal of the systemic inflammation.


Subject(s)
Biomarkers/blood , Hyperparathyroidism, Primary/blood , Inflammation/blood , C-Reactive Protein/analysis , Case-Control Studies , Female , Follow-Up Studies , Humans , Hyperparathyroidism, Primary/complications , Hyperparathyroidism, Primary/surgery , Inflammation/etiology , Lipopolysaccharide Receptors/blood , Longitudinal Studies , Male , Matrix Metalloproteinase 9/blood , Microarray Analysis , Middle Aged , Parathyroidectomy , Prospective Studies , Receptor for Advanced Glycation End Products , Receptors, Immunologic/blood , S100 Calcium-Binding Protein A4 , S100 Proteins/blood
2.
Nutr Diabetes ; 4: e124, 2014 Jun 30.
Article in English | MEDLINE | ID: mdl-24979153

ABSTRACT

BACKGROUND: A combined procedure of sleeve gastrectomy and duodenal switch (SG+DS) has been applied to the treatment of super obesity. The aim of the present study was to test whether duodenal switch alone (DS) leads to similar weight loss and changes in lipid metabolism as SG+DS. METHODS: Male Sprague-Dawley rats underwent sham surgery (Sham, N=7), duodenal switch alone (DS, N=5) or sleeve gastrectomy followed by duodenal switch (SG+DS, N=5). Body weight, feed and water intakes, and ambulatory activity were recorded 2 months post surgery. Tissue and faecal lipids, faecal bile acids, plasma cytokines and lipid metabolism-related gene expression in adipose tissue and liver were analysed. RESULTS: Daily energy intake, relative feed uptake, ambulatory activity and body weight reduction were similar between DS and SG+DS rats. The hepatic triacylglycerol content was higher and faecal secretion of triacylglycerol was lower after SG+DS compared to DS (P<0.05). Faecal bile acid secretion was higher in SG+DS than in DS rats (P<0.05) despite similar hepatic CYP7A1mRNA level. Plasma levels of proinflammatory cytokines interleukin (IL)-1b, IL-2, IL-4, IL-5, IL-6, IL-12, granulocyte-macrophage colony stimulating factor and tumour necrosis factor alpha were higher in SG+DS than in DS rats (P<0.05). CONCLUSIONS: Although DS and SG+DS had similar efficacy in terms of body weight loss, SG+DS resulted in a poorer regulation of lipid metabolism than DS.

3.
Am J Physiol Endocrinol Metab ; 306(2): E210-24, 2014 Jan 15.
Article in English | MEDLINE | ID: mdl-24302006

ABSTRACT

Repeated attempts to lose weight by temporary dieting may result in weight cycling, eventually further gain of body fat, and possible metabolic adaptation. We tested this with a controlled experiment in C57BL/6J mice subjected to four weight cycles (WC), continuous hypercaloric feeding (HF), or low-fat feeding (LF). To search for genes involved in an adaptive mechanism to former weight cycling and avoid acute effects of the last cycle, the last hypercaloric feeding period was prolonged by an additional 2 wk before euthanization. Total energy intake was identical in WC and HF. However, compared with HF, the WC mice gained significantly more total body mass and fat mass and showed increased levels of circulating leptin and lipids in liver. Both the HF and WC groups showed increased adipocyte size and insulin resistance. Despite these effects, we also observed an interesting maintenance of circulating adiponectin and free fatty acid levels after WC, whereas changes in these parameters were observed in HF mice. Global gene expression was analyzed by microarrays. Weight-cycled mice were characterized by a downregulation of several clock genes (Dbp, Tef, Per1, Per2, Per3, and Nr1d2) in adipose tissues, which was confirmed by quantitative PCR. In 3T3-L1 cells, we found reduced expression of Dbp and Tef early in adipogenic differentiation, which was mediated via cAMP-dependent signaling. Our data suggest that clock genes in adipose tissue may play a role in metabolic adaptation to weight cycling.


Subject(s)
Adipose Tissue/growth & development , Adipose Tissue/metabolism , Body Weight/physiology , CLOCK Proteins/genetics , Weight Gain/drug effects , 3T3-L1 Cells , Adaptation, Physiological/drug effects , Adaptation, Physiological/genetics , Adipogenesis/genetics , Adiposity/physiology , Animals , CLOCK Proteins/metabolism , Caloric Restriction/adverse effects , Gene Expression/drug effects , Liver/drug effects , Liver/metabolism , Male , Mice , Mice, Inbred C57BL
4.
J Intern Med ; 272(6): 583-91, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22757621

ABSTRACT

OBJECTIVES: Primary hyperparathyroidism (PHPT) has been associated with low-grade inflammation and elevated risk of cardiovascular disease (CVD). In inflammatory conditions, interferon-γ (IFN-γ) activity is enhanced and a decreased circulating concentration of vitamin B6 is often observed. Such changes in IFN-γ activity or vitamin B6 levels have been associated with increased incidence of CVD. The aim of the study was to investigate systemic markers of IFN-γ-mediated immune activation, such as neopterin, the kynurenine-to-tryptophan ratio (KTR) and kynurenine pathway metabolites, as well as B6 vitamers in patients with PHPT. DESIGN/SUBJECTS: A total of 57 patients with PHPT and a control group of 20 healthy blood donors were included in this study. PHPT patients who responded positively to parathyroidectomy were followed for 6 months. Forty-three patients participated in the longitudinal study in which blood samples were taken at inclusion and 1, 3 and 6 months after surgery. RESULTS: Plasma concentrations of the B6 vitamers pyridoxal 5'-phosphate (PLP) (P = 0.007) and pyridoxal (P = 0.013) were significantly lower in the patient group compared to healthy control subjects. An increase in the KTR indicated that the kynurenine pathway of tryptophan metabolism was altered in PHPT patients (P = 0.015). During the initial 6 months after surgery, levels of PLP (P < 0.001) and anthranilic acid (P < 0.001) increased significantly, whereas neopterin decreased (P = 0.018). CONCLUSIONS: The results of this study demonstrate altered levels of vitamin B6 and the KTR in PHPT patients, both of which may reflect cellular immune activation. These abnormalities should be considered in relation to the increased risk of CVD previously observed in patients with PHPT.


Subject(s)
Hyperparathyroidism, Primary , Kynurenine/metabolism , Parathyroidectomy/methods , Tryptophan/metabolism , Vitamin B 6 , Aged , Biomarkers , Cardiovascular Diseases/etiology , Cardiovascular Diseases/metabolism , Cardiovascular Diseases/prevention & control , Female , Humans , Hyperparathyroidism, Primary/complications , Hyperparathyroidism, Primary/metabolism , Hyperparathyroidism, Primary/surgery , Immunity, Cellular , Immunologic Factors , Inflammation/metabolism , Interferon-gamma/metabolism , Longitudinal Studies , Male , Middle Aged , Monitoring, Immunologic/methods , Neopterin/metabolism , Postoperative Care/methods , Risk Factors , Vitamin B 6/blood , Vitamin B 6/metabolism , ortho-Aminobenzoates/metabolism
5.
Int J Obes (Lond) ; 36(9): 1195-202, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22143616

ABSTRACT

BACKGROUND: Adipose tissue is critical for systemic metabolic health. Identifying key factors regulating adipose tissue function is a research priority. The NR4A subfamily of nuclear receptors (NRs) (NR4A1/NUR77, NR4A2/NURR1 and NR4A3/NOR1) has emerged as important proteins in different disease states and in the regulation of metabolic tissues, particularly in liver and muscle. However, the expression of the NR4A members in human adipose tissue has not previously been described, and their target genes are largely unknown. OBJECTIVE: To determine whether the NR4As are differentially expressed in human adipose tissue in obesity, and identify potential NR4A target genes. DESIGN: Prospective analysis of s.c. adipose tissue before and 1 year after fat loss, and during in vitro differentiation of primary human preadipocytes. Case-control comparison of omental (OM) adipose tissue. SUBJECTS: A total of 13 extremely obese patients undergoing biliopancreatic diversion with duodenal switch for fat loss, 12 extremely obese patients undergoing laparoscopic sleeve gastrectomy and 37 lean individuals undergoing hernia repair or laparotomy were included in the study. Measurements were done by quantitative PCR gene expression analysis of the NR4A members and in silico promoter analysis based on microarray data. RESULTS: There was a strong upregulation of the NR4As in extreme obesity and normalization after fat loss. The NR4As were expressed at the highest level in stromal-vascular fraction compared with adipocytes, but were downregulated in both fractions after fat loss. Their expression levels were also significantly higher in OM compared with s.c. adipocytes in obesity. The NR4As were downregulated during differentiation of primary human preadipocytes. Moreover, the NR4As were strongly induced within 30 min of tissue incubation. Finally, promoter analysis revealed potential NR4A target genes involved in stress response, immune response, development and other functions. Our data show altered adipose tissue expression of the NR4As in obesity, suggesting that these stress responsive nuclear receptors may modulate pathogenic potential in humans.


Subject(s)
Adipocytes/metabolism , Adipose Tissue/metabolism , DNA-Binding Proteins/metabolism , Nuclear Receptor Subfamily 4, Group A, Member 1/metabolism , Nuclear Receptor Subfamily 4, Group A, Member 2/metabolism , Obesity, Morbid/metabolism , Receptors, Steroid/metabolism , Receptors, Thyroid Hormone/metabolism , Weight Loss , Adult , DNA-Binding Proteins/genetics , Down-Regulation , Female , Follow-Up Studies , Gene Expression Regulation , Humans , Male , Middle Aged , Norway , Nuclear Receptor Subfamily 4, Group A, Member 1/genetics , Nuclear Receptor Subfamily 4, Group A, Member 2/genetics , Obesity, Morbid/surgery , Prospective Studies , Receptors, Steroid/genetics , Receptors, Thyroid Hormone/genetics , Signal Transduction , Transcription Factors , Up-Regulation , Weight Loss/genetics
6.
Pharmacogenomics J ; 11(2): 100-7, 2011 Apr.
Article in English | MEDLINE | ID: mdl-20309015

ABSTRACT

The role of pharmacogenomics and tamoxifen was investigated by analyzing several polymorphisms of cytochrome P450 and SULT1A1 gene in a nested case control study from the Italian Tamoxifen Prevention Trial. This study included 182 Caucasian subjects, 47 breast cancer (BC) cases and 135 matched controls. We used the AmpliChip CYP450 Test to screen 33 alleles of CYP2D6 and 3 of CYP2C19. One more variant for CYP2C19*17 and two single-nucleotide polymorphisms for the gene SULT1A1 were also performed. By using the AmpliChip CYP450 Test, out of 182 subjects, we identified 8 poor metabolizer (PM), 17 intermediate metabolizer (IM), 151 extensive metabolizer (EM) and 3 ultrarapid metabolizer (UM). PM women allocated to the tamoxifen arm showed a higher risk of developing BC compared to the remaining phenotypes (P=0.035). In an exploratory analysis, among 58 women with a CYP2D6*2A allele, 9 BCs were diagnosed in the placebo arm and only 1 in the tamoxifen arm (P=0.0001). CYP2C19 and SULT1A1 polymorphisms did not show any correlation with tamoxifen efficacy. Tamoxifen showed reduced efficacy in CYP2D6 PMs in the chemoprevention setting. Conversely, the CYP2D6*2A allele may be associated with increased efficacy of tamoxifen. These findings support the relevance of pharmaco-genomics in tailoring tamoxifen treatment.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Aryl Hydrocarbon Hydroxylases/genetics , Breast Neoplasms/prevention & control , Cytochrome P-450 CYP2D6/genetics , Drug Resistance, Neoplasm/genetics , Tamoxifen/therapeutic use , Arylsulfotransferase/genetics , Case-Control Studies , Clinical Trials as Topic , Cytochrome P-450 CYP2C19 , Female , Humans , Italy , Middle Aged , Polymorphism, Single Nucleotide , Treatment Outcome
7.
Br J Cancer ; 101(8): 1253-60, 2009 Oct 20.
Article in English | MEDLINE | ID: mdl-19755984

ABSTRACT

BACKGROUND: Acquired resistance to endocrine therapy in breast cancer is poorly understood. Characterisation of the molecular response to aromatase inhibitors in breast cancer tissue may provide important information regarding development of oestrogen hypersensitivity. METHODS: We examined the expression levels of nuclear receptor co-regulators, the orphan nuclear receptor liver receptor homologue-1 and HER-2/neu growth factor receptor using real-time RT-PCR before and after 13-16 weeks of primary medical treatment with the aromatase inhibitors anastrozole or letrozole. RESULTS: mRNA expression of the steroid receptor co-activator 1 (SRC-1) and peroxisome-proliferator-activated receptor gamma co-activator-1alpha (PGC-1alpha) was correlated (P=0.002), and both co-activators increased during treatment in the patient group as a whole (P=0.008 and P=0.032, respectively), as well as in the subgroup of patients achieving an objective treatment response (P=0.002 and P=0.006). Although we recorded no significant change in SRC-3/amplified in breast cancer 1 level, the expression correlated positively to the change of SRC-1 (P=0.002). Notably, we recorded an increase in HER-2/neu levels during therapy in the total patient group (18 out of 26; P=0.016), but in particular among responders (15 out of 21; P=0.008). CONCLUSION: Our results show an upregulation of co-activator mRNA and HER-2/neu during treatment with aromatase inhibitors. These mechanisms may represent an early adaption of the breast cancer cells to oestrogen deprivation in vivo.


Subject(s)
Aromatase Inhibitors/therapeutic use , Breast Neoplasms/drug therapy , Heat-Shock Proteins/genetics , Histone Acetyltransferases/genetics , Receptor, ErbB-2/genetics , Transcription Factors/genetics , Breast Neoplasms/metabolism , Female , Gene Expression Regulation, Neoplastic , Humans , Neoadjuvant Therapy , Nuclear Receptor Coactivator 1 , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha , RNA, Messenger/analysis , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Estrogen/analysis
8.
Ann Oncol ; 19(1): 56-61, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17947222

ABSTRACT

BACKGROUND: Tamoxifen is hydroxylated by cytochrome P450 (CYP) 2D6 to the potent metabolites 4-hydroxytamoxifen (4OHtam) and 4-hydroxy-N-demethyltamoxifen (4OHNDtam), which are both conjugated by sulphotransferase (SULT)1A1. Clinical studies indicate that CYP2D6 and SULT1A1 genotypes are predictors for treatment response to tamoxifen. Therefore, we examined the relationship between CYP2D6 genotype, SULT1A1 genotype, SULT1A1 copy number and the pharmacokinetics of tamoxifen. PATIENTS AND METHODS: The serum levels of tamoxifen and metabolites of 151 breast cancer patients were measured by high-pressure liquid chromatography-tandem mass spectrometry. The CYP2D6 and SULT1A1 polymorphisms and SULT1A1 copy number were determined by long PCR, PCR-based restriction fragment length polymorphism, DNA sequencing and fluorescence-based PCR. RESULTS: The levels of 4OHtam, 4OHNDtam and N-demethyltamoxifen were associated with CYP2D6 predicted enzymatic activity (P < 0.05). The SULT1A1 genotype or copy number did not influence the levels of tamoxifen and its metabolites. However, the ratios of N-demethyltamoxifen/tamoxifen and N-dedimethyltamoxifen/N-demethyltamoxifen were related to SULT1A1 genotype. CONCLUSION: CYP2D6 and SULT1A1 genotypes may partly explain the wide inter-individual variations in the serum levels of tamoxifen and its metabolites. We propose that therapeutic drug monitoring should be included in studies linking CYP2D6 and SULT1A1 genotypes to clinical outcome.


Subject(s)
Antineoplastic Agents, Hormonal/pharmacokinetics , Arylsulfotransferase/genetics , Breast Neoplasms/drug therapy , Cytochrome P-450 CYP2D6/genetics , Selective Estrogen Receptor Modulators/pharmacokinetics , Tamoxifen/pharmacokinetics , Adult , Aged , Aged, 80 and over , Arylsulfotransferase/metabolism , Biotransformation/genetics , Breast Neoplasms/blood , Breast Neoplasms/enzymology , Cytochrome P-450 CYP2D6/metabolism , Female , Gene Dosage , Gene Frequency , Genotype , Humans , Middle Aged , Norway , Polymorphism, Restriction Fragment Length , Tamoxifen/analogs & derivatives , Tamoxifen/blood
9.
J Chromatogr A ; 1082(1): 6-14, 2005 Jul 29.
Article in English | MEDLINE | ID: mdl-16038189

ABSTRACT

We have developed a method for the determination of tamoxifen (tam) and its metabolites 4-hydroxytamoxifen (4OHtam), N-demethyltamoxifen (NDtam), N-dedimethyltamoxifen (NDDtam), tamoxifen-N-oxide (tamNox), and 4-hydroxy-N-demethyltamoxifen (4OHNDtam) in 50 microl human serum. Serum proteins were precipitated with acetonitrile. Deuterated-tamoxifen (D5 tam) was added as internal standard. Sample supernatant was injected into an on-line reversed-phase extraction column coupled with a C18 analytical column and analytes were detected by tandem mass spectrometry. The lower limits of quantification were 0.25 ng/mL for 4OHtam, NDtam and tam, 1.0 ng/mL for NDDtam and tamNox. Ranges of within- and between-day variation were 2.9-15.4% and 4.4-12.9%, respectively.


Subject(s)
Chromatography, Liquid/methods , Mass Spectrometry/methods , Tamoxifen/blood , Breast Neoplasms/drug therapy , Chemical Fractionation/methods , Humans , Sensitivity and Specificity , Tamoxifen/analogs & derivatives , Tamoxifen/metabolism , Tamoxifen/therapeutic use
10.
J Steroid Biochem Mol Biol ; 84(2-3): 361-7, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12711024

ABSTRACT

We investigated the kinetics of tamoxifen (tam) in immunodeficient mice and rats after oral treatment and compared drug and metabolite profile in nude rat serum and tissues after oral and subcutaneous (s.c.) routes of administration. The serum levels were compared to those observed in man. After oral dosing in mice, tam and the potent metabolite 4-hydroxytamoxifen (4-hydroxytam), were detectable in liver and lung tissue, but not in serum. The levels of 4-hydroxytam in these tissues were significantly higher than those of tam, a profile opposite to that observed in rat and man. In rats and man, the 4-hydroxytam/tam serum concentration ratios were 0.16 and 0.02, respectively. Compared to oral route, the s.c. pellets yielded only trace amounts of the demethylated derivatives of tam in rats. Thus, the kinetics of tam observed in the present study suggest that the nude rat may represent a preferable animal model in studying the pharmacokinetics of tam and that, the oral route yielded higher serum and tissue levels of tam and metabolites than equivalent s.c. pellet implants.


Subject(s)
Estrogen Antagonists/administration & dosage , Estrogen Antagonists/pharmacokinetics , Tamoxifen/analogs & derivatives , Tamoxifen/administration & dosage , Tamoxifen/pharmacokinetics , Administration, Oral , Animals , Chromatography, High Pressure Liquid , Injections, Subcutaneous , Kinetics , Mice , Mice, Nude , Rats , Rats, Nude , Species Specificity , Time Factors
11.
Scand Cardiovasc J ; 34(3): 315-20, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10935780

ABSTRACT

OBJECTIVE: Extra corporeal circulation of human blood is used daily in lifesaving procedures such as open-heart surgery and extracorporeal membrane oxygenation (ECMO). But extracorporeal circulation also induces activation of various cascade reactions in the blood. The objective of this study was to evaluate the effects of hemofiltration on cytokine release and removal as well as on platelet activation and consumption. MATERIAL AND METHODS: Two complete ECMO systems, each of them holding a hollow fiber oxygenator, a bladder box, PVC tubing and a roller pump were perfused for 24 h with fresh, heparinized human blood. A hemofilter was added to one of the paired systems. Blood samples were collected from both circuits before start, and at 0.5, 1, 3, 12 and 24 h of perfusion. A total of 8 paired experiments was performed. RESULTS: The plasma concentration of interleukin (IL)1beta, IL-6 and IL-8, as well as of IL-1 receptor antagonist (IL-1ra) increased over time in both systems, but consistently lower levels were observed in the filter circuits compared to the controls. Only minor parts of these cytokines could be assayed in the ultrafiltrate. No significant difference in platelet count and platelet membrane expression of glycoprotein Ib was observed between the circuits. CONCLUSIONS: By adding a hemofilter to the ECMO circuit, it is possible to reduce the plasma concentration of interleukins without significantly affecting platelet activation and consumption.


Subject(s)
Cytokines/blood , Extracorporeal Membrane Oxygenation , Hemofiltration , Platelet Activation/physiology , Hemoglobinometry , Humans , In Vitro Techniques , Leukocyte Count , Neutrophils/immunology , Platelet Count , Platelet Membrane Glycoproteins/metabolism , beta-Thromboglobulin/metabolism
12.
Virchows Arch ; 433(6): 579-81, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9870694

ABSTRACT

We report on a mucoepidermoid carcinoma (MEC) of the lung in a 6-year-old girl with a t(11;19)(q14-21;p12) as the sole karyotypic abnormality. An apparently identical t(11;19) has been reported previously in a MEC originating from the major and minor salivary glands. Our findings indicate that the t(11;19) is intimately associated with the mucoepidermoid phenotype and may be used as a diagnostic marker for this tumour type.


Subject(s)
Carcinoma, Mucoepidermoid/genetics , Lung Neoplasms/genetics , Translocation, Genetic , Biomarkers, Tumor , Carcinoma, Mucoepidermoid/metabolism , Carcinoma, Mucoepidermoid/pathology , Child , Chromosomes, Human, Pair 11 , Chromosomes, Human, Pair 19 , Female , Humans , Immunohistochemistry , Karyotyping , Lung Neoplasms/metabolism , Lung Neoplasms/pathology
13.
Artif Organs ; 22(10): 859-63, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9790084

ABSTRACT

The objective of this study was to determine the degree of leukocyte activation, as measured by cytokine release, in circulating blood during experimental extracorporeal circulation. Complete in vitro extracorporeal membrane oxygenation (ECMO) circuits were used, and 9 experiments were performed. Whole blood stored at 37 degrees C was used as the control. Blood samples were withdrawn before the start of perfusion and at 24 h of perfusion. Statistically significant releases of interleukin (IL)-1beta, IL-8, and IL-1 receptor antagonist were observed in the perfusion circuits compared to both the control blood and baseline values. Also, increases in plasma tumor necrosis factor (TNF)alpha and IL-6 were seen after 24 h of perfusion although these changes did not reach statistical significance. These results indicate that extracorporeal circulation induced leukocyte activation and cytokine release. These reactions might, as an additional trauma, deteriorate the situation in an already severely ill patient. A search for methods to counteract this untoward activation seems warranted.


Subject(s)
Cytokines/blood , Extracorporeal Circulation , Adult , Anticoagulants/blood , Blood Cell Count , Chemotaxis, Leukocyte/physiology , Critical Illness , Equipment Design , Extracorporeal Circulation/instrumentation , Extracorporeal Circulation/methods , Hemoglobins/analysis , Heparin/blood , Humans , Interleukin-1/blood , Interleukin-6/blood , Interleukin-8/blood , Leukocyte Count , Leukocytes/physiology , Neutrophils/cytology , Oxygenators , Platelet Count , Receptors, Interleukin-1/antagonists & inhibitors , Tumor Necrosis Factor-alpha/analysis
14.
J Cardiovasc Surg (Torino) ; 39(2): 181-91, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9639003

ABSTRACT

BACKGROUND: The extended use of cardiopulmonary bypass (CPB) in cardiac surgery is limited because of damage to blood which in adults has been assessed by alterations in blood cell rheology. Blood trauma assessment in children is difficult because of the restrictions in sample volume and frequency but needs to be established from time to time in order to study the tolerance to new surgical and extracorporeal techniques. MATERIALS AND METHODS: Fourteen pediatric patients undergoing cardiac surgery with CPB for congenital heart disease corrections were studied. Whole blood, red blood cell and white blood cell rheology (filterability) were monitored before, during and after CPB using the St. George filtrometer that used small amounts of blood. RESULTS: The results showed that all the rheologic parameters were altered during the blood trauma of CPB and were outside the reference values before, during and after CPB. CONCLUSIONS: This suggested that blood cell rheologic disturbances did not recover soon after CPB and this may be of interest in long term follow-up to understand responses and recovery patterns to disease and interventions associated with pediatric heart surgery using CPB.


Subject(s)
Cardiopulmonary Bypass , Erythrocyte Deformability , Heart Defects, Congenital/blood , Blood Cell Count , Cardiac Surgical Procedures , Cardiopulmonary Bypass/adverse effects , Child , Child, Preschool , Female , Follow-Up Studies , Heart Defects, Congenital/surgery , Hematocrit , Hemorheology , Humans , Infant , Male , Postoperative Period
15.
Perfusion ; 13(3): 187-91, 1998 May.
Article in English | MEDLINE | ID: mdl-9638716

ABSTRACT

The objective of this study was to evaluate the effect of albumin priming on platelet consumption and activation during long-term perfusion. Two identical in vitro extracorporeal membrane oxygenation circuits were used; one was primed with Ringer's solution containing human serum albumin, the other with Ringer's solution only. Fresh heparinized human blood was pooled, divided between the two systems and circulated for 24 h at 37 degrees C. Platelet count, plasma concentration of betathromboglobulin (BTG), platelet membrane density of glycoprotein (GP) Ib and of GPIIb/IIIa were assayed before the start and at 0.5, 1, 3, 12 and 24 h of perfusion. In total, seven experiments were performed. We found that during the first hour of perfusion, slightly higher platelet counts (p = 0.058) and lower BTG values (p = 0.0005) were observed in the circuits primed with albumin, compared to the control circuits. No statistically significant differences were observed for the platelet membrane expression of GPIb and GPIIb/IIIa. We conclude that albumin priming appears to transiently prevent platelet consumption and activation during long-term perfusion.


Subject(s)
Extracorporeal Membrane Oxygenation , Perfusion , Platelet Activation/drug effects , Serum Albumin/pharmacology , Humans , Platelet Count/drug effects , Platelet Glycoprotein GPIIb-IIIa Complex/analysis , Platelet Glycoprotein GPIb-IX Complex/analysis , Solutions/pharmacology , beta-Thromboglobulin/analysis
16.
Ann Thorac Surg ; 65(5): 1335-41, 1998 May.
Article in English | MEDLINE | ID: mdl-9594863

ABSTRACT

BACKGROUND: The increased bleeding tendency observed after cardiopulmonary bypass is caused in part by thrombocytopenia and impaired platelet function induced by the procedure. Previous in vitro studies have shown that nitric oxide (NO) added to the oxygenator sweep gas reduces platelet activation during experimental perfusion. We evaluated the effect of 40 ppm of NO, added to the oxygenator sweep gas, on platelet consumption and activation in patients undergoing cardiopulmonary bypass. METHODS: Twenty patients scheduled to undergo cardiopulmonary bypass were randomized to either the control or the NO arm of the study. Their platelet count, plasma beta-thromboglobulin level, platelet membrane glycoprotein Ib and IIb/IIIa levels, adenosine diphosphate-induced platelet aggregation, plasma nitrate level, and plasma hemoglobin were assayed before, during, and after cardiopulmonary bypass. RESULTS: After operation, slightly higher platelet counts were observed in the NO-treated patients than in the control patients, which might indicate a lower degree of platelet adhesion to the artificial surfaces of the extracorporeal circuit. However, this difference did not reach statistical significance. In addition, a difference in platelet membrane expression of glycoprotein Ib was seen between the NO and control groups after operation; the platelets of the control patients had significantly higher glycoprotein Ib expression than those of the NO-treated patients. The results of platelet aggregometry indicated preserved platelet function in both the NO-treated and control patients. The blood methemoglobin levels also were low in both groups. CONCLUSIONS: Nitric oxide might reduce the platelet consumption encountered during cardiopulmonary bypass without having any adverse effect on platelet function, as reflected by the preserved aggregation response seen in our patients. However, the best route of NO administration and the optimum dose remain to be established.


Subject(s)
Blood Platelets/drug effects , Coronary Artery Bypass , Heart Valve Prosthesis Implantation , Nitric Oxide/therapeutic use , Adenosine Diphosphate/pharmacology , Aged , Blood Platelets/physiology , Cardiopulmonary Bypass/adverse effects , Cardiopulmonary Bypass/instrumentation , Female , Follow-Up Studies , Hemoglobins/analysis , Humans , Male , Methemoglobin/analysis , Middle Aged , Nitrates/blood , Nitric Oxide/administration & dosage , Oxygenators , Platelet Activation/drug effects , Platelet Adhesiveness/drug effects , Platelet Aggregation/drug effects , Platelet Count/drug effects , Platelet Glycoprotein GPIIb-IIIa Complex/analysis , Platelet Glycoprotein GPIb-IX Complex/analysis , Platelet Glycoprotein GPIb-IX Complex/drug effects , Postoperative Hemorrhage/prevention & control , Thrombocytopenia/prevention & control , beta-Thromboglobulin/analysis
17.
Artif Organs ; 22(12): 1045-51, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9876097

ABSTRACT

The purpose of this study was to compare blood cell activation during in vitro long-term perfusion using 2 parallel in vitro extracorporeal membrane oxygenation (ECMO) systems. We compared two substantially different perfusion systems, an assistance respiratoire extra corporelle (AREC) system on one hand, containing an AREC pump, silicon tubing, and a hollow-fiber oxygenator, and a centrifugal pump system, on the other hand, containing a Biomedicus centrifugal pump, PVC tubing, and a membrane oxygenator. We measured the platelet count using an automated blood cell counter. Platelet activation was evaluated using a flow cytometric technique for the platelet membrane expression of glycoproteins and ELISA for the plasma concentration of beta-thromboglobulin (beta-TG), a platelet specific protein released into the blood upon platelet activation. The neutrophil count was assayed using an automated blood cell counter and the plasma concentration of cytokines using an ELISA kit. A significant difference between the two systems was observed in terms of the platelet membrane expression of glycoprotein (GP)Ib (p=0.0001) and GPIIb/IIIa (p=0.0037), indicating a lower degree of platelet activation in the AREC system. The concentration of neutrophils was significantly lower in the centrifugal system (p=0.002) compared to the AREC system. The neutrophil membrane expression of CD11b was significantly lower (p=0.0067) in the AREC system, indicating a lower degree of neutrophil activation compared to the centrifugal pump system. A significantly lower degree of hemolysis, as expressed by plasma hemoglobin, was observed in the AREC pump system (p=0.0491). In conclusion, lower degrees of the platelet membrane expression of GPIb and GPIIb/IIIa and of the neutrophil membrane expression of CD11b were observed in the AREC system, indicating a lower degree of platelet and neutrophil activation in this system. No significant difference between the two systems as to the plasma concentration of interleukin (IL)-1beta, IL-6, or IL-8 could be recorded. Further studies are warranted to specify the role of each individual component of the two systems.


Subject(s)
Blood Platelets/physiology , Extracorporeal Membrane Oxygenation/instrumentation , Neutrophils/physiology , CD11 Antigens/analysis , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Hemoglobins/analysis , Humans , In Vitro Techniques , Interleukins/blood , Leukocyte Count , Platelet Activation , Platelet Count , Platelet Membrane Glycoproteins/metabolism , beta-Thromboglobulin/analysis
18.
Endocr Res ; 24(3-4): 497-504, 1998.
Article in English | MEDLINE | ID: mdl-9888530

ABSTRACT

Several lines of evidence have suggested that the nuclear receptor Steroidogenic Factor-1 (SF-1 or Ad4BP) may be directly involved in the cAMP-dependent regulation of steroid hydroxylase genes in adrenocortical cells. In the bovine CYP17 gene, which encodes the cytochrome P450 17alpha-hydroxylase, an SF-1 site is present within cAMP-responsive sequence 2 (CRS2) and mutations which interfere with SF-1 binding correlate with decreases in cAMP-stimulated transcription of a linked reporter gene. In order to determine whether the cAMP response relies on structures within SF-1 itself, mutations and deletions were introduced. We demonstrate that even a single point mutation (E454A) in the transactivating AF-2 domain drastically reduces the ability of SF-1 to mediate cAMP-dependent transcription. Furthermore, the mutation results in a protein which acts in a dominant negative fashion with respect to cAMP-dependent regulation of the bovine CYP17 gene. Finally, we demonstrate that the coactivators CBP and SRC-1 are limiting with respect to cAMP-induced CRS2-dependent transcription in Y1 adrenocortical tumor cells, suggesting that part of the action of cAMP may be to influence the interaction of SF-1 with other cofactors via the AF-2 domain.


Subject(s)
Cyclic AMP/physiology , Receptors, Cytoplasmic and Nuclear/physiology , Steroid 17-alpha-Hydroxylase/physiology , Adrenal Cortex Neoplasms/pathology , Animals , CREB-Binding Protein , Cattle , DNA-Binding Proteins/genetics , DNA-Binding Proteins/physiology , Fushi Tarazu Transcription Factors , Gene Deletion , Genes, Dominant/physiology , Histone Acetyltransferases , Homeodomain Proteins , Mice , Mutation/genetics , Nuclear Proteins/physiology , Nuclear Receptor Coactivator 1 , Point Mutation/physiology , Steroidogenic Factor 1 , Trans-Activators/physiology , Transcription Factors/genetics , Transcription Factors/physiology , Transcription, Genetic/physiology , Tumor Cells, Cultured
19.
Acta Paediatr ; 86(10): 1082-4, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9350889

ABSTRACT

The aim of the study was to reveal differences in carbohydrate metabolism in children with cyanotic congenital heart diseases (CHD). Thirteen children with diseases of these kinds were investigated with regard to glucose tolerance and insulin secretion and comparisons were made with healthy controls of the same age. Investigations included an intravenous glucose tolerance test, insulin response to the glucose load in plasma and insulin secretion rate. The results reveal lower fasting glucose levels and signs of a higher insulin secretion rate in the relatively few patients in the CHD group where C-peptide measurements were performed, but no differences in glucose tolerance. The reasons for the differences are unclear, but the chronic increases in circulating catecholamines in combination with the impaired nutritional status of these children with CHD are probably the most important factors. We conclude that these divergences in carbohydrate metabolism should be emphasized in the care of children with CHD.


Subject(s)
Glucose/metabolism , Heart Defects, Congenital/metabolism , Insulin/metabolism , C-Peptide/blood , Heart Defects, Congenital/blood , Humans , Infant , Insulin/blood , Nutritional Status , Transposition of Great Vessels/metabolism
20.
Endocrinology ; 138(10): 4373-83, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9322953

ABSTRACT

cAMP and Ca2+ acted together with the acute phase cytokine interleukin-1beta (IL-1beta) to inhibit hepatocyte DNA replication. At sub-basal activity of cAMP-dependent protein kinase (PKA), neither IL-1beta nor the Ca2+-elevating hormone vasopressin affected hepatocyte proliferation. Basal level of PKA activity permitted IL-1beta action. Increased PKA activity also permitted vasopressin action and sensitized further towards IL-1beta, which acted at 10-50 pM concentrations. Vasopressin acted via Ca2+/calmodulin-dependent protein kinase II (CaMKII), and its action was mimicked by the serine/threonine phosphatase inhibitor microcystin, which activates CaMKII. Inhibitors (KN93 and KT5926) of CaMKII selectively counteracted the effects of vasopressin and microcystin on hepatocyte proliferation at concentrations similar to those required to inhibit CaMKII in vitro. Two-dimensional gel electrophoresis of 32P-prelabeled hepatocytes revealed a common set of proteins phosphorylated in response to vasopressin and microcystin. Their phosphorylation was counteracted by CaMKII inhibitor (KT5926). Phosphorylation of the CaMKII substrate phenylalanine hydroxylase (PAH; EC 1.14.16.1) was used as an endogenous marker of CaMKII activation. It was found that treatment of the cells with vasopressin or microcystin increased the phosphorylation of PAH, and that the vasopressin-induced PAH phosphorylation was inhibited by KT5926. In conclusion, the Ca2+-elevating hormone vasopressin potentiated the antiproliferative effects of cAMP and IL-1beta through CaMKII activation.


Subject(s)
Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Carbazoles , Cyclic AMP/pharmacology , Indoles , Interleukin-1/pharmacology , Liver/cytology , Liver/enzymology , Peptides, Cyclic/pharmacology , Vasopressins/pharmacology , 1-Methyl-3-isobutylxanthine/pharmacology , Alkaloids/pharmacology , Animals , Benzylamines/pharmacology , Calcium/pharmacology , Calcium-Calmodulin-Dependent Protein Kinases/antagonists & inhibitors , Calcium-Calmodulin-Dependent Protein Kinases/physiology , Cell Division/drug effects , Cell Division/physiology , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Cyclic AMP-Dependent Protein Kinases/metabolism , Cyclic AMP-Dependent Protein Kinases/physiology , DNA/metabolism , Drug Synergism , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Liver/physiology , Male , Microcystins , Phenylalanine Hydroxylase/antagonists & inhibitors , Phenylalanine Hydroxylase/metabolism , Phosphoproteins/analysis , Phosphorylation , Rats , Rats, Wistar , Signal Transduction/drug effects , Signal Transduction/physiology , Sulfonamides/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...